Clinical Trials Logo

Healthy Participants clinical trials

View clinical trials related to Healthy Participants.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06441318 Recruiting - Clinical trials for Healthy Participants

A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants

Start date: July 12, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the effect of povorcitinib on the QT/QTc Interval in healthy participants.

NCT ID: NCT06416800 Recruiting - Clinical trials for Healthy Participants

A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics When Administered Orally to Healthy Adult Participants

Start date: June 19, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics When Administered Orally to Healthy Adult Participants.

NCT ID: NCT06411730 Recruiting - Clinical trials for Healthy Participants

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity

Start date: May 31, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and drug levels of orally administered BMS-986368 in healthy participants, healthy elderly participants, and healthy participants of japanese ethnicity.

NCT ID: NCT06368440 Recruiting - Clinical trials for Healthy Participants

A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese Participants

Start date: May 15, 2024
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of oral AZD6793 in healthy Japanese and Chinese participants.

NCT ID: NCT06357520 Recruiting - Clinical trials for Healthy Participants

A Study to Investigate the Pharmacokinetics of Baxdrostat When Given Alone and in Combination With Itraconazole in Healthy Participants

Start date: April 16, 2024
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to assess the effect of itraconazole on the pharmacokinetic (PK) of baxdrostat.

NCT ID: NCT06356948 Recruiting - Clinical trials for Healthy Participants

Rate of Tranexamic Acid Administration on Blood Pressure (RateTXA) Study.

RateTXA
Start date: March 30, 2024
Phase: Phase 4
Study type: Interventional

Tranexamic acid is a well-established treatment for post-partum hemorrhage. This study aims to examine the effect of tranexamic acid administration rates on blood pressure changes over 1 minute compared to 10 minutes in healthy pregnant patients scheduled for cesarean delivery.

NCT ID: NCT06356259 Recruiting - Clinical trials for Healthy Participants

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants

Start date: June 7, 2023
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics with intravenous(IV) administration of IRX-010 in Healthy Participants.

NCT ID: NCT06350747 Recruiting - Clinical trials for Healthy Participants

The Effect of Laughter Yoga on Nurses' Perceived Stress, Sleep Quality, and Burnout Levels

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The aim of the study was to investigate the effects of laughter yoga on nurses' perceived stress, sleep quality, and burnout levels.

NCT ID: NCT06349473 Recruiting - Clinical trials for Healthy Participants

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B)

Start date: April 15, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with severe Hemophilia A or Hemophilia B, with or without inhibitors (Part B).

NCT ID: NCT06348303 Recruiting - Clinical trials for Healthy Participants

Study to Assess Drowsiness, Cognition, Fall Risk After Metaxalone 640 mg and Metaxalone 800 mg

Start date: March 15, 2024
Phase: Phase 4
Study type: Interventional

Every participant will receive Metaxalone in two (2) stages, one week after the other. A single dose of each Metaxalone dose will be taken one (1) time after a high fat meal which must be eaten within 30 minutes. Every participant will be given written tests to measure drowsiness, reaction time and thinking process and will also be asked to take walking tests to assess fall risk. Participation in this study will last approximately 2-4 weeks.